From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Therapy with Folate and Vitamins B12 and B6 After Coronary Angioplasty

Patients who received 6 months of homocysteine-lowering therapy had lower rates of restenosis at 1 year than did placebo recipients.

Results from a recently published Swiss study showed that homocysteine-lowering therapy reduced the 6-month incidence of restenosis in patients who underwent coronary angioplasty (Journal Watch Dec 4 2001). Now, the same investigators report results that include more patients and longer follow-up.

A total of 553 patients underwent percutaneous coronary angioplasty; about half the lesions also were stented. Patients then were randomized to receive 6-month daily courses of homocysteine-lowering therapy (1 mg folic acid, 400 µg vitamin B12, and 10 mg vitamin B6) or placebo. At 1 year, a composite endpoint (including revascularization, myocardial infarction, and death) occurred significantly less often with active treatment than with placebo (15% vs. 23%). The benefit was attributable largely to a lower rate of repeat revascularization of initial target lesions in the active-treatment group (10% vs. 16%).

Comment: A 6-month course of this inexpensive intervention appears to provide protection against restenosis for at least a year after coronary angioplasty. The presumed mechanism is the homocysteine-lowering effect of the folate/B12/B6 combination: Plasma homocysteine levels dropped by about 30% in patients who received active treatment. In ongoing studies, investigators are examining whether longer-term treatment with folate and vitamins B6 and B12 will confer additional benefits in patients with coronary disease.

— Allan S. Brett, MD

Published in Journal Watch General Medicine September 6, 2002

Citation(s):

Schnyder G et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: A randomized controlled trial. JAMA 2002 Aug 28; 288:973-9.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2002. Massachusetts Medical Society. All rights reserved.